How CORE-ABR grades it
Intrinsic resistance applied: ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, cefazolin, cefotaxime, ceftriaxone, ertapenem, the tetracyclines (including tigecycline), trimethoprim and TMP-SMX. Few oral options remain; fluoroquinolones are graded against detected genes.
What the report shows for Pseudomonas aeruginosa
- Detected or not detected, with Ct, limit of detection and cycles above LOD — see PCR reporting.
- A short pathogen summary, including colonizer likelihood where it applies.
- A graded column on the antibiogram, and therapy options by scenario on the P.A.C.T. report.
- When not detected, it is still listed among targets tested.
Resistance genes CORE-ABR applies
When detected, each of these genes is applied to Pseudomonas aeruginosa only for the agents its mechanism defeats.
Class A beta-lactamase (KPC / SHV)Carbapenemase (KPC) or ESBL (SHV variants) production5 organisms on panelClass B metallo-beta-lactamase (IMP / VIM)Metallo-carbapenemase production5 organisms on panelClass D beta-lactamase (OXA)Oxacillinase production4 organisms on panelqnrA / qnrBPlasmid-mediated quinolone resistance7 organisms on panelqnrSPlasmid-mediated quinolone resistance3 organisms on panel
Tagged
Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.